University of Bergen

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

Retrieved on: 
Thursday, November 30, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Brain, Safety, Research, Deficit spending, Parkinson's disease, Cell Metabolism, ChromaDex, Disease, Tremor, Stiffness, Nicotinamide adenine dinucleotide, Neuron, Nature Communications, Agonal respiration, Dementia, University, Person, Mitochondrion, Translational research, Haukeland University Hospital, University of Bergen, NAD, Pharmaceutical industry, Medical device, PD

These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

Key Points: 
  • These results build upon previous research led by Dr. Tzoulis ( Cell Metabolism ) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.
  • Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.
  • This study establishes the short-term safety of 3,000 mg NR daily and allows the clinical community to explore high-dose options in future therapeutic trials.
  • Notably, all of Prof. Tzoulis’ clinical research is academically-driven and based largely on public funding.

NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Retrieved on: 
Tuesday, October 17, 2023
Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Neoplasm, Professor, Cancer, Sarcoma, Frontiers, Biomarker, University of Pittsburgh Medical Center, NEC, AI, OUH, University, Artificial intelligence, Oslo University Hospital, PFS, Monroe Dunaway Anderson, Blood, University of Bergen, Patient, NOI, Medical imaging, Immunology

The authors sequenced tumor samples and blood from patients who participated in the pivotal SARC028 clinical trial and received the pembrolizumab checkpoint inhibition therapy.

Key Points: 
  • The authors sequenced tumor samples and blood from patients who participated in the pivotal SARC028 clinical trial and received the pembrolizumab checkpoint inhibition therapy.
  • They then used their AI-based neoantigen prediction technology, the NEC Immune Profiler, to investigate whether high quality neoantigens in cooperation with the immune cell composition in the tumor improved PFS.
  • The NOI researchers believe that AI can play a future role in guiding future personalized medicine and cancer diagnostics, ultimately improving outcomes for patients with cancer.
  • These and future advances in this field may lead to improved clinical outcome for patients suffering from rare cancers treated with cancer immunotherapy,” said Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity, and a senior author in the study.

Global Collaboration Leads to New Discoveries in Lightning Research

Retrieved on: 
Wednesday, August 16, 2023
Bismuth, Radiation, Partnership, Altitude, University, Goddard Space Flight Center, National Oceanic and Atmospheric Administration, Armstrong Flight Research Center, Geostationary Operational Environmental Satellite, NRL, International Space Station, Marshall Space Flight Center, University of Bergen, Eye, GLM, Lightning, Optics, FEGS, NASA, ER-2, LIS, Materials International Space Station Experiment, Gamma, Tropical Rainfall Measuring Mission, Jet fuel, Medical imaging, Telescope, Communications satellite

Naval Research Laboratory (NRL), and three NASA centers have just completed a month of flights to study lightning and the vast energy fields around thunderclouds in our atmosphere.

Key Points: 
  • Naval Research Laboratory (NRL), and three NASA centers have just completed a month of flights to study lightning and the vast energy fields around thunderclouds in our atmosphere.
  • Their new observations will help scientists gain further insight into how lightning forms and help them better predict when storms could turn severe.
  • ALOFT is short for Airborne Lightning Observatory for Fly's Eye GLM Simulator and Terrestrial gamma-ray flashes.
  • The Marshall team also contributed to the commercially built Geostationary Lightning Mapper (GLM) aboard the National Oceanic and Atmospheric Administration's Geostationary Operational Environmental Satellite (GOES-R) series.

Bergen Prepares to Host International Conference on Hansen's Disease Marking 150 Years Since the Discovery of the Leprosy Bacillus

Retrieved on: 
Monday, June 19, 2023
Goodwill, United Nations, University, Leprosy, United Nations special rapporteur, Hope, Nippon Foundation, Mycobacterium, University of Bergen, Stradivarius, History, Person, Donald Mackay Medal, Discovery, Tropical medicine, WHO Goodwill Ambassador, Human rights, Nippon Music Foundation, Knowledge, WHO, Ministry of Health and Care Services, Conference, London School of Hygiene and Tropical Medicine, World Health Organization, Disease, Pharmaceutical industry, Hygiene

The conference, which will be held in the city where Norwegian Dr. Gerhard Armauer Hansen made his groundbreaking finding, will also be streamed online.

Key Points: 
  • The conference, which will be held in the city where Norwegian Dr. Gerhard Armauer Hansen made his groundbreaking finding, will also be streamed online.
  • Many countries and international organizations, led by the World Health Organization, now aim to achieve zero leprosy—zero disease, zero disability and zero discrimination—.
  • Achieving this goal will require close collaboration between partners, which the Bergen meeting aims to foster.
  • The Bergen International Conference on Hansen's Disease: 150 Years Since the Discovery of the Leprosy Bacillus brings together key stakeholders in the leprosy field for sessions focused on medical challenges, human rights and dignity, and history preservation—the three pillars on which the Sasakawa Leprosy (Hansen's Disease) Initiative structures its activities against the disease.

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Friday, June 16, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, University of Helsinki, Science, Human, Cell Metabolism, University, PD, Heart failure, Metabolism, CERP, Science Advances, NR, Placebo, LVEF, Spinal cord, Research fellow, Clinical trial, Ageing, NAD, University of Oslo, Philip Morris External Research Program, ChromaDex, Research, Brain, Inflammation, Affiliation, Mitochondrion, DSM-IV codes, University of Washington School of Medicine, Trial of the century, Associate, Haukeland University Hospital, University of Bergen, City, Publication, Parkinson's disease, Patient, Division, Heart, University of Copenhagen Faculty of Health and Medical Sciences, University of Oulu, Diabetes, Safety, Copenhagen, Dietary supplement, Pharmaceutical industry, Medical device, Nicotinamide riboside, Cardiology

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.

Cytovation Strengthens its Board of Directors for Next Phase of Development

Retrieved on: 
Thursday, September 15, 2022
Norwegian Government Security and Service Organisation, CFO, Biomedical Research, Company, Haukeland University Hospital, New Board, Sandwater, Industry, Patient, Doctor of Philosophy, Board, BMS, Boehringer Ingelheim, Mohn, University, Oslo Stock Exchange, University of Bergen, Pharmaceutical industry, Management, MD, Innovation Norway

Current CEO of Mohn Drilling, Mohn combines over 16 years of industry experience with an extensive scientific background in biomedical research.

Key Points: 
  • Current CEO of Mohn Drilling, Mohn combines over 16 years of industry experience with an extensive scientific background in biomedical research.
  • Representing Canica AS, a large, privately owned investment company operating out of Norway and Switzerland, which co-led the Series A round together with Sandwater, Cytovation has welcomed yvind Kongstun Arnesen to the Board.
  • Stein Christian Mohn, Chair of Cytovation, commented: "I am delighted to be taking on the role of Chairperson at Cytovation, having witnessed the company's impressive progress during my time on the Board.
  • I would like to welcome our new board members, each of whom brings considerable experience to Cytovation as we move into the next phase of development.

European Patients Have Begun Receiving Transfusions with Hemanext ONE® RBC Processing and Storage System

Retrieved on: 
Wednesday, September 7, 2022
RBC, CE marking, Patient, University, CEO, Technology, Safety, De novo protein synthesis theory of memory formation, Research, O2, Carbon, Doctor of Philosophy, Entrepreneurship, White blood cell, Aplastic anemia, LR, University of Bergen, Oslo University Hospital, Collection, Red blood cell, Degenerative disease, Department, NIH, Quality of life, De novo, Immunology, Lymphatic system, Transfusion medicine, MD, Classification, CO2, Company, FDA, Mark (given name), Certification, Trial of the century, MDS, Pharmaceutical industry, Medical device

LEXINGTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Hemanext Inc ., a leading innovator in blood processing, storage, and transfusion technology, today announced that it has initiated the rollout of its Hemanext ONE RBC (Red Blood Cell) Processing and Storage System in Europe.

Key Points: 
  • LEXINGTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Hemanext Inc ., a leading innovator in blood processing, storage, and transfusion technology, today announced that it has initiated the rollout of its Hemanext ONE RBC (Red Blood Cell) Processing and Storage System in Europe.
  • Doctors have begun transfusing patients suffering from hematological malignancies using RBCs processed and stored with the Hemanext ONE system, as part of a post-market clinical study in Bergen, Norway.
  • Hemanext received CE Mark Certification for its RBC Processing & Storage System in April 2021 and plans to roll out Hemanext ONE across additional European markets in the coming months.
  • In Europe, the system is CE Marked for the processing and storage CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared and processed with the HEMANEXT ONE system within 24hours of collection.

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Nicotinamide Riboside (NR) Supplementation in Patients with Parkinson’s Disease (PD)

Retrieved on: 
Wednesday, March 2, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ageing, PD, Degenerative disease, Neuron, ChromaDex, Harvard Medical School, Patient, Tremor, Neuroimaging, Research, Massachusetts General Hospital, Regulatory affairs, Cell Metabolism, Risk, Neurodegeneration, Dementia, Security (finance), Cytokine, Annual report, Hospital, Mitochondrion, University, Haukeland University Hospital, University of Bergen, Parkinson's disease, NAD, Metabolism, SEC, Company, Disease, Securities Act of 1933, Translational research, Trial of the century, Government budget balance, Neurology, Cerebrospinal fluid, Clinical trial, An Act to exempt a particular class of securities from the Securities and Exchange Act, Respiration (physiology), Drug Quality and Security Act, Brain, Human, NASDAQ, Pharmaceutical industry, Medical device, Medical imaging

The clinical trial was part of the ChromaDex External Research Program (CERP) and investigated the companys proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with Parkinsons disease (PD).

Key Points: 
  • The clinical trial was part of the ChromaDex External Research Program (CERP) and investigated the companys proprietary Niagen ingredient (patented nicotinamide riboside, or NR) in patients with Parkinsons disease (PD).
  • Parkinsons disease is a common neurodegenerative disorder, affecting more than 10 million people worldwide.
  • As such, this study assessed NR as a potential therapeutic strategy targeting mitochondrial function and energy metabolism in PD patients.
  • We look forward to further research aimed at understanding the role of NR supplementation in Parkinsons patients.